Caribou Biosciences, Inc. (CRBU)

3.7250 -0.0350 (-0.93%) As of 02:40PM EDT. Market open.

Caribou Biosciences, Inc.

2929 7th Street
Suite 105
Berkeley, CA 94710
United States
510 982 6030
https://cariboubio.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 158

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Rachel E. Haurwitz Ph.D.	Co-Founder, CEO, President & Director	833.47k	N/A	1986
Ms. Ruhi A. Khan M.B.A.	Chief Business Officer	573.9k	N/A	1975
Mr. Jason V. O'Byrne M.B.A.	CFO & Principal Accounting Officer	586.36k	N/A	1969
Mr. Daniel Poon	Vice President of Operations & Information Technology	N/A	N/A	N/A
Ms. Amy Figueroa C.F.A.	Vice President of Investor Relations & Corporate Communications	N/A	N/A	N/A
Ms. Barbara G. McClung Esq., J.D.	Chief Legal Officer & Corporate Secretary	608.38k	N/A	1955
Ms. Reigin Zawadzki	Chief People Officer	N/A	N/A	N/A
Mr. Ryan Fischesser	Vice President of Finance & Controller	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

Corporate governance

Caribou Biosciences, Inc.’s ISS governance QualityScore as of 1 April 2024 is 6. The pillar scores are Audit: 3; Board: 5; Shareholder rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.